Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

PHASE2RecruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

June 25, 2012

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Aplastic Anemiade Novo Myelodysplastic SyndromeMyelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome

Interventions

BIOLOGICAL

Anti-Thymocyte Globulin

Given IV

DRUG

Cyclosporine

Given PO

BIOLOGICAL

Filgrastim

Given SC

DRUG

Methylprednisolone

Given IV or PO

BIOLOGICAL

Pegfilgrastim

Given SC

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER